|
 DEC.27,
2011 Interprotein
Corporation has entered into an
Agreeement with Takeda Pharmaceutical in the
field of Small Molecule Inhibitors against
Protein-protein Interaction. PharmaJapan
NOV.21,
2011 Ajinomoto Pharmaceuticals Co., Ltd.
and Interprotein Corporation
Sign a Joint R&D and Commercialization
Agreement for Small Molecule PPI
(protein-protein interaction) Inhibitors.
This is the Second Collaboration Tie-up between
Two Companies. Release
Sep.14, 2011 US NIH's
Recombinant DNA Advisory Committee made a
Recommendation for Ph.I/II study
of Anaeropharma Science
Cancer Drug Candidate APS001F. RAC
Meeting
AUG, 2011 A
Kinopharma's Compound could be
a Potent Anti-virus Drug Candidate against
Dengue Viruses for which there is No Effective
Cure, See NEWS.
JUN.
2011 Interprotein has
outlined the company's Platform Drug Design
Technology called "INTENDD" in its Web
Site.
APR.13,
2011 Interprotein is
Qualified as a Participant for "Space Open
Laboratory" at JAXA (the Japan Aerospace
Exploration Agency) for its Small Molecule PPI
(protein-protein interaction) Inhibitor
Programs. Japanese
Release
FEB.10,
2011 Carna
Biosciences, Inc. and KinoPharma,
Inc. Sign a Joint Research Agreement
for Drug Discovery for Neurodegenerative
Disorders.
NOV.01,
2010 Anaeropharma Science
Has Fundraised 700 million yen – Capital
Contribution by Innovation Network Corporation of
Japan (INCJ).
OCT.01,
2010 Interprotein and
LegoChem Biosciences sign collaboration
agreement to develop VEGF inhibitor to treat
solid tumor
OCT.01,
2010 Eisai and Anaeropharma
Science Conclude Agreements Concerning
the Novel Anticancer Agent APS001 and a Drug
Delivery System Using Bifidobacterium Longum. Release
SEP.27,
2010 Interprotein
Corporation and Ajinomoto
Pharmaceuticals Co., Ltd Sign
a Collaboration Agreement on Drug Discovery
Research.
AUG.21,
2009 Anaeropharma CEO is
interviewed. See News
MAY.21, 2009 Moved to
new office
FEB.28,
2007 Interprotein
Corporation and Evotec Sign
Collaboration Agreement to Develop Small
Molecule Interleukin 6 (IL-6) Inhibitors to
Treat Inflammatory Diseases. Release
OCTOBER, 2006 A new
portfolio company, Interprotein
AUGUST, 2006 A new portfolio
company, Kinopharma
JUN.20, 2006 One of the
portfolio companies changed its name
MAY.19, 2005 A new
portfolio company, CellGentech
MAR.02, 2005 A new
portfolio company, RT Solutions
DEC.14, 2004 Watervein has
completed a final closing of its venture
fund.
Sep.30, 2004
Watervein made an investment into Anaeropharma
Science.
APR.01, 2004 SITE OPEN
| 
